Octenidine Versus Dispase Gels for Wound Healing After Cryosurgery Treatment in Patients with Basal Cell Carcinoma

Adv Exp Med Biol. 2023:1425:591-601. doi: 10.1007/978-3-031-31986-0_57.

Abstract

For a specific group of patients with basal cell carcinoma (small, low risk), cryosurgery could be the suggested treatment, which results in the formation of an ulcer in the lesion area. The proteolytic enzymes' contribution to the wound healing is an ongoing research goal. Preclinical animal experiments in the Laboratory of the Pharmaceutical Technology Department of the National and Kapodistrian University of Athens have showed that a dose of 5 U/mL of dispase gel after the formation of tissue rashes, significantly promoted wound healing. Herein, a feasibility study in 16 patients enrolled by the First Department of Dermatology of Andreas Syggros Hospital was designed: 5 U/mL of dispase gel (once every 3 days) versus a drug reference containing octenidine (daily administration). The evaluation of the healing effect, safety, and tolerance was done on days 1 (cryosurgery), 2, 7, 21, and 60. The study end point was considered either the ulcer complete healing or the eighth week since treatment initiation. Wound healing was faster with dispase gel and hemoglobin reduced rapidly after the seventh day. Yet, hydration was higher in the control group. Our non-parametric analysis provides evidence that the dispase gel shows faster healing compared to the reference drug, in humans, meriting further investigation in larger human sample sizes before massive production of the product.

Keywords: Clinical trial; Debridement; Dispase; Enzymes; Octenidine; Skin pharmacology; Wound healing.

MeSH terms

  • Animals
  • Carcinoma, Basal Cell* / drug therapy
  • Carcinoma, Basal Cell* / surgery
  • Cryosurgery* / adverse effects
  • Gels
  • Humans
  • Skin Neoplasms* / drug therapy
  • Skin Neoplasms* / surgery
  • Ulcer
  • Wound Healing

Substances

  • octenidine
  • dispase
  • Gels